ストックスクリーナーアプリを入手
3.08
2.33%
0.07
アフターアワーズ：
3.09
0.010
+0.32%
Pliant Therapeutics Inc (PLRX) 最新ニュース
Levi & Korsinsky Reminds Shareholders of an Investigation into Pliant Therapeutics, Inc. (PLRX) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Connect - Markets Insider
Pliant Therapeutics (PLRX) to Release Quarterly Earnings on Tuesday - MarketBeat
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation - Markets Insider
Pliant Therapeutics Inc (PLRX): Major Improvements, Worth A Look - Stocks Register
Wells Fargo downgrades Pliant Therapeutics Inc (PLRX) stock to an Equal weight - Knox Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Investors to Learn More About the Investigation - Markets Insider
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc.PLRX - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Investors to Inquire about Securities Investigation - Markets Insider
Pliant Therapeutics chief business officer Hull sells $178,500 in stock - MSN
Pliant Therapeutics' chief medical officer sells $206,973 in stock - MSN
Pliant Therapeutics general counsel Mike Ouimette sells $261,100 in stock - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Reach Out - Markets Insider
What is HC Wainwright's Forecast for PLRX FY2029 Earnings? - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Price Target Lowered to $10.00 at Needham & Company LLC - MarketBeat
Pliant Therapeutics' (PLRX) Market Perform Rating Reiterated at Oppenheimer - MarketBeat
Pliant Therapeutics Initiates Outside Expert Panel to Review BEACON-IPF Trial Data - Defense World
Pliant Therapeutics (NASDAQ:PLRX) Given Hold Rating at Canaccord Genuity Group - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Stockholders to Reach Out - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Stockholders to Connect - ACCESS Newswire
Pliant Therapeutics' chief human resource officer sells $41,892 in stock - MSN
Pliant Thera lines up experts to review BEACON-IPF Phase IIb/III trial - The Pharma Letter
Pliant Therapeutics stock hits 52-week low at $2.52 - MSN
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Hold" by Brokerages - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Downgraded to Sector Perform Rating by Royal Bank of Canada - MarketBeat
Stifel maintains Pliant Therapeutics stock buy rating amid study pause By Investing.com - Investing.com Canada
Sector Update: Health Care Stocks Mixed Thursday Afternoon -February 13, 2025 at 02:03 pm EST - Marketscreener.com
Sector Update: Health Care Stocks Mixed Thursday Afternoon - TradingView
Pliant Therapeutics Moves Forward With Expert Panel Following BEACON-IPF Trial Enrollment Pause - Nasdaq
Sector Update: Health Care -February 13, 2025 at 01:45 pm EST - Marketscreener.com
Stifel maintains Pliant Therapeutics stock buy rating amid study pause - MSN
Pliant stock jumps 28% on bexotegrast study update - MSN
Pliant Therapeutics to Assemble Expert Panel to Review BEACON-IPF Trial Data; Shares Jump - Marketscreener.com
Pliant stock jumps 28% on bexotegrast study update (PLRX:NASDAQ) - Seeking Alpha
Pliant Therapeutics (NASDAQ:PLRX) Reaches New 52-Week LowWhat's Next? - MarketBeat
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis - The Manila Times
Pliant Therapeutics Announces Next Steps Following DSMB - GlobeNewswire
Pliant's IPF Drug Trial Hits Unexpected Hurdle: Expert Panel Called for Urgent Review - StockTitan
What is HC Wainwright’s Estimate for PLRX FY2029 Earnings? - Defense World
Canaccord Genuity Group Reaffirms Hold Rating for Pliant Therapeutics (NASDAQ:PLRX) - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Sets New 1-Year LowTime to Sell? - MarketBeat
Pliant Therapeutics stock hits 52-week low at $2.52 By Investing.com - Investing.com Nigeria
Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 8.7%Should You Sell? - MarketBeat
Pliant Therapeutics, Inc. Company Investigated by the Portnoy Law Firm - GlobeNewswire
Pliant pauses mid-stage trial for lung disease therapy - MSN
Canaccord Genuity cuts Pliant to hold on study setback - MSN
Oppenheimer cuts Pliant Therapeutics stock rating amid trial pause - MSN
Pliant Therapeutics (NASDAQ:PLRX) Shares Down 8.7%Should You Sell? - MarketBeat
Pliant stock plunges 61% amid study pause, downgrades - MSN
Citigroup Downgrades Pliant Therapeutics (PLRX) - MSN
Pliant Therapeutics Pauses Enrollment and Dosing in BEACON-IPF TrialOn February 7, 2025, Pliant Therapeutics, Inc. (NASDAQ: PLRX) disclosed that, subsequent to a prespecified data review and recommendations made by the trial’s independent Data Saf - Defense World
Canaccord Genuity cuts Pliant to hold on study setback (PLRX:NASDAQ) - Seeking Alpha
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):